Wall Street analyst estimates for ImageneBio Inc (IMA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc.
Valuation Ratios
| Price / Book | 0.55 |
| EV / EBITDA | 0.72 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $990000 | $13.8M | $9.2M | $31.0M | $15.6M | $9.2M | $3.5M | $800000 |
| Cost of Revenue | $39.0M | $24.9M | $44.8M | $47.1M | $64.3M | $1.0M | $1.5M | $1.0M |
| Gross Profit | -$38.0M | -$11.2M | -$35.7M | -$16.1M | -$48.7M | $8.1M | $2.0M | -$233000 |
| Research & Development | $38.6M | $24.9M | $44.8M | $47.1M | $64.3M | $59.7M | $32.1M | $28.5M |
| Selling, General & Admin | $2.9M | $7.3M | $8.9M | $18.0M | $22.2M | $24.9M | $8.4M | $20.7M |
| Operating Expenses | $41.5M | $7.3M | $8.9M | $18.0M | $22.2M | $83.6M | $39.0M | $48.2M |
| Operating Income | -$40.9M | -$18.5M | -$44.5M | -$34.1M | -$70.9M | -$75.4M | -$37.0M | -$48.5M |
| EBITDA | -$40.4M | -$18.2M | -$44.2M | -$33.6M | -$68.0M | -$67.3M | -$35.0M | -$44.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$40.9M | -$16.8M | -$44.3M | -$34.1M | -$68.8M | -$68.3M | -$36.6M | -$45.7M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -$162000 | $13000 | -$350000 |
| Net Income | -$40.9M | -$16.8M | -$44.3M | -$34.1M | -$68.8M | -$68.2M | -$36.6M | -$45.3M |
| EPS | $-13.68 | $-5.63 | $-14.81 | $-11.38 | $-22.80 | $-19.60 | $-40.52 | $-9.64 |
| EPS (Diluted) | $-13.68 | $-5.63 | $-14.81 | $-11.38 | $-22.80 | $-19.60 | $-40.52 | $-9.64 |
| Shares Outstanding (Diluted) | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $3.5M | $1.2M | $5.4M |
Price
| Price | $4.93 |
| Market Cap | $56M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARTV · CNTB · CNTX · IFRX · KLRS · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of IMA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks